OPKO Health Valuation Multiples

OPKO Health Overview

About OPKO Health

OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.

Founded

1991

HQ

Employees

3.0K

Website

opko.com

Sectors

BiopharmaceuticalsDiagnostics & GenomicsBioTechHealthTech

Financials (LTM)

Revenue: $590M

EBITDA: ($124M)

EV

$969M

Valuation Multiples

Multiples.vc

Start free trial

OPKO Health Financials

OPKO Health reported last 12-month revenue of $590M and negative EBITDA of ($124M).

In the same LTM period, OPKO Health generated $262M in gross profit, ($124M) in EBITDA losses, and had net loss of ($222M).

OPKO Health P&L

In the most recent fiscal year, OPKO Health reported revenue of $607M and EBITDA of ($41M).

OPKO Health expects next 12-month revenue of XXX and NTM EBITDA of XXX

OPKO Health Stock Performance

OPKO Health has current market cap of $941M, and enterprise value of $969M.

OPKO Health's stock price is $1.24.

OPKO Health Valuation Multiples

OPKO Health trades at 1.6x EV/Revenue multiple, and (7.8x) EV/EBITDA.

OPKO Health Financial Valuation Multiples

As of April 20, 2026, OPKO Health has market cap of $941M and EV of $969M.

Equity research analysts estimate OPKO Health's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

OPKO Health has a P/E ratio of (4.2x).

OPKO Health Margins & Growth Rates

OPKO Health's revenue in the last 12 month declined by (5%).

OPKO Health's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

OPKO Health's rule of 40 is (31%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

OPKO Health's rule of X is (45%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

OPKO Health Public Comps

See public comps and valuation multiples for other Biopharmaceuticals and Diagnostics & Genomics comps.

OPKO Health M&A Activity

OPKO Health acquired XXX companies to date.

Last acquisition by OPKO Health was on XXXXXXXX, XXXXX. OPKO Health acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

OPKO Health Investment Activity

OPKO Health invested in XXX companies to date.

OPKO Health made its latest investment on XXXXXXXX, XXXXX. OPKO Health invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).